Arbutus Biopharma Corp (NASDAQ:ABUS) has been assigned an average rating of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $13.80.
A number of research firms recently weighed in on ABUS. JMP Securities reissued an “outperform” rating and set a $13.00 price target (up from $12.00) on shares of Arbutus Biopharma in a research note on Wednesday, October 4th. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma in a research note on Tuesday. Zacks Investment Research downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday. BidaskClub raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. Finally, ValuEngine downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th.
A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Arbutus Biopharma by 2.7% in the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,035 shares in the last quarter. OxFORD Asset Management LLP increased its stake in Arbutus Biopharma by 89.9% in the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 39,436 shares in the last quarter. RTW Investments LP increased its stake in Arbutus Biopharma by 1.1% in the third quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after purchasing an additional 56,457 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in Arbutus Biopharma in the third quarter valued at approximately $1,393,000. 59.97% of the stock is owned by hedge funds and other institutional investors.
Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.21. equities research analysts expect that Arbutus Biopharma will post -1.29 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/20/arbutus-biopharma-corp-abus-receives-consensus-rating-of-hold-from-analysts.html.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.